Expression of IFITM1 in chronic myeloid leukemia patients

Leuk Res. 2005 Mar;29(3):283-6. doi: 10.1016/j.leukres.2004.07.007.

Abstract

We investigated the peripheral blood gene expression profile of interferon induced transmembrane protein 1 (IFITM1) in sixty chronic myeloid leukemia (CML) patients classified according to new prognostic score (NPS). IFITM1 is a component of a multimeric complex involved in the trunsduction of antiproliferative and cell adhesion signals. Expression level of IFITM1 was found significantly different between the high- and low-risk groups (P = 9.7976 x 10(-11)) by real-time reverse transcription polymerase chain reaction (RT-PCR). Higher IFITM1 expression correlated with improved survival (P = 0.01). These results indicate that IFITM1 expression profiling could be used for molecular classification of CML, which may also predict survival.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antigens, Differentiation
  • Biomarkers, Tumor / analysis*
  • Female
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / classification
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
  • Male
  • Membrane Proteins / biosynthesis*
  • Middle Aged
  • Prognosis
  • Reverse Transcriptase Polymerase Chain Reaction
  • Survival Analysis

Substances

  • Antigens, Differentiation
  • Biomarkers, Tumor
  • Membrane Proteins
  • leu-13 antigen